A Study to Assess the Safety and Performance of SurgiClot® in the Treatment of Cancellous Bone Bleeding

Inclusion Criteria: * Patients undergoing a planned elective orthopaedic or spinal surgical procedure. Spinal surgery can be the entire spine although it should be confined to one or two-level fusions e.g. one or two level cervical, or thoracic or lumbar. * Patient has an intraoperative bleeding site involving cancellous bone that the surgeon would typically treat with another topical haemostatic agent to control the bleeding. * Patient has normal liver function * The subject is willing and able to comply with the requirements of the study protocol, including the six weeks follow-up evaluation. Exclusion Criteria: * Is unable or unwilling to return for the follow-up visit. * The subject has had surgery at the intended application site ≤ 6 months before the current surgical procedure. * Active infection at the surgical site. * Pregnancy, as determined by urine pregnancy test, or breast feeding. * Pre-operative platelet count \< 150,000, INR \> 1.3, and/or APTT \> 32.4. * Pre-operative anaemia (Hb \< 110 g/L in females, Hb \< 120 g/L in males). * Use of anticoagulant therapy (e.g., coumadin, heparin, clopidogrel), non-steroidal anti-inflammatory medications or fish oil supplements within 7 days of the surgery except for aspirin. (maximum dose 150 mg per day) * Patient with a blood dyscrasia. * Presence of a spinal tumour, intradural pathology, or prior spinal fusion surgery at the same target site. * Participation in another clinical trial with an investigational drug or device within the past 30 days. * Known allergy to human fibrinogen, human thrombin, or porcine-derived products. * Compromised immune system. * The use of a haemostatic agent is contraindicated for the subject. * Fibrinolytic disorders requiring intraoperative antifibrinolytic treatment. * Haematological disease (thromboembolic events, haemoglobinopathy, coagulopathy or haemolytic disease) * Significant co-morbidities: Previous myocardial infarction (MI); severe ischemic heart disease (New York Heart Association Class III, IV); severe pulmonary disease; chronic renal failure; hepatic failure; uncontrolled hypertension. * Subject is unwilling to receive blood products.